Business context and reporting period
The supplied filing is Oncocyte Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2023, not a filing under the metadata name “Insight Molecular Diagnostics Inc.” Oncocyte develops and commercializes precision diagnostic tests and provides pharma services. Its continuing business focused on DetermaIO, DetermaCNI, VitaGraft, and Pharma Services.
On February 16, 2023, Oncocyte completed the sale of approximately 70% of Razor Genomics and transferred DetermaRx-related assets and liabilities to Razor. Razor’s results are presented as discontinued operations; Oncocyte retained approximately 30% ownership. The transaction brought no monetary consideration for the equity sale but was intended to eliminate DetermaRx development and commercialization costs.
Financial performance and position
Amounts below are in U.S. dollars; financial statement amounts are in thousands unless noted.
- Revenue: Continuing-operations revenue was $297,000, down 22% from $380,000. Total revenue including discontinued Razor operations was $718,000, down 50% from $1.424 million.
- Gross margin: Continuing-operations gross margin was $10,000, about 3% of revenue, versus $247,000, about 65%, in Q1 2022. Cost of revenue, including acquired-intangible amortization, was $287,000 versus $133,000.
- Operating expenses: R&D was $2.127 million, up 6%; sales and marketing was $695,000, up 161%; and G&A was $3.412 million, down 40%.
- Profit and EPS: Continuing-operations income was $5.959 million; net income including discontinued operations was $3.033 million, compared with a $10.291 million net loss a year earlier. Basic and diluted net income per share were each $0.02. The quarter’s reported profit was substantially affected by a noncash $18.307 million gain from revaluing contingent consideration.
- Cash flow: Operating activities used $9.672 million, compared with $13.277 million used in Q1 2022. Investing activities used no cash; financing activities used $28,000. Cash, cash equivalents, and restricted cash declined $9.700 million to $13.503 million.
- Liquidity: At March 31, cash and cash equivalents were $11.803 million, marketable equity securities were $553,000, and restricted cash was $1.700 million. Current assets were $15.648 million and current liabilities $9.430 million.
- Debt and obligations: The company reported no outstanding bank loan principal; lease liabilities totaled approximately $3.325 million. Series A preferred stock had a $5.532 million carrying value and a $6.182 million liquidation preference. Contingent consideration liabilities were $27.355 million.
- Other balance-sheet measures: Total assets were $82.800 million, total liabilities $39.335 million, and accumulated deficit $257.643 million. Intangible assets, net, were $56.661 million.
Material changes versus the prior comparable period
- Net income improved from a $10.291 million loss to $3.033 million of income. This does not represent an equivalent improvement in underlying operations: the $18.307 million contingent-consideration fair-value gain was a major driver, alongside $4.950 million of intangible-asset impairment and $1.283 million of disposal/held-for-sale losses.
- Continuing revenue declined $83,000; management attributed lower Pharma Services activity to fewer contracts and lower licensing revenue partly to the end of Burning Rock revenue.
- G&A decreased $2.235 million, while R&D and sales and marketing increased by $120,000 and $429,000, respectively.
- Razor discontinued-operations revenue was $421,000 versus $1.044 million; its net loss was $2.926 million versus $6.878 million. The 2023 period includes Razor only through the February sale closing.
- Cash and cash equivalents fell from $19.993 million at year-end 2022 to $11.803 million at quarter-end. The contingent-consideration liability fell from $45.662 million to $27.355 million, primarily reflecting revised estimates of future payment timing and valuation assumptions.
Outlook, commentary, risks, and unusual items
- Management stated that available cash, cash equivalents, and marketable securities were expected to fund operations for at least 12 months from the financial-statement issuance date. It also said additional capital would be needed and that continued operations depend on revenue generation, execution of its plan, and financing. No specific revenue or earnings guidance was provided.
- On April 3, 2023, after quarter-end, Oncocyte agreed to a registered direct offering of approximately 45.6 million shares for gross proceeds of about $13.9 million. It used about $1.1 million to redeem preferred shares and could elect to redeem more. The filing also reports a May 5 common-share count of 164,821,077, versus 119,278,821 shares at March 31.
- On April 12, 2023, the company announced a workforce reduction of approximately 20%; management said it expected the action to extend cash runway into 2024. Estimated severance and benefit costs were approximately $300,000 in Q2 2023.
- The Series A preferred stock carries a 6% cumulative dividend and is generally redeemable by April 8, 2024. While it remains outstanding, terms include an $8 million minimum unrestricted, unencumbered cash requirement and restrictions on certain additional debt and senior or pari passu securities.
- Oncocyte recorded a $4.950 million impairment of acquired DetermaIO in-process R&D following revised strategy and forecasts. It also recorded $1.283 million of disposal and held-for-sale losses on laboratory equipment.
- The collaboration agreement with Life Technologies was terminated in February 2023; the filing states Oncocyte owed $749,000 of certain development costs as of March 31.
- Management reported disclosure controls were ineffective at March 31 because of previously identified material weaknesses involving complex accounting standards and unusual or non-routine transactions. Remediation efforts were ongoing.
- Key risks include recurring operating losses and cash use, need for further capital and potential shareholder dilution, reimbursement and commercialization uncertainty, contingent consideration and preferred-stock obligations, and possible impacts from COVID-19. The filing reported no material litigation and no material changes to the risk factors in the 2022 Form 10-K.
Important facts for investors to verify
- Reconcile the reported Q1 profit to operating cash use and assess how much earnings depended on the noncash contingent-consideration gain and other unusual items.
- Confirm the post-quarter offering’s final proceeds, share issuance, preferred-stock redemptions, and resulting dilution; the filing gives slightly different share totals in its subsequent-event disclosures.
- Assess cash runway using actual post-quarter cash, restricted cash, preferred-stock cash minimum terms, planned spending, and expected obligations.
- Track DetermaIO, DetermaCNI, and VitaGraft development, clinical progress, regulatory status, and reimbursement coverage, as well as Pharma Services contract revenue and customer concentration.
- Review the assumptions behind the contingent-consideration valuation and intangible-asset impairment, and monitor remediation of the disclosed control weaknesses.